Human studies mainly used short-term intravenous DSIP injections under controlled research conditions, typically at 25 nmol/kg, but these studies were small, short-duration, and not designed to establish long-term safety or optimal dosing
Among the most promising candidates, supported by phase 1 and 2 clinical trials, is cagrilintide, a long-acting amylin and calcitonin receptor agonist
Do Patients Need to Stay on These Forever
doi: 10.1002/dmrr.3353 12 VermaSMcMurrayJJV
Feelings can influence how progress is viewed It is normal to feel disappointed when weight loss slows
Writing a GLP-1 prescription without medical indication or supervision could lead to adverse reactions and severe side effects for patients, and the physician runs the risk of losing their medical license